Stifel reiterates Buy on Faron Pharmaceuticals after cash update secures runway to key trial readout

What Brokers Say Health Written by: Ian Lyall 12:30 Wed 26 Aug 2026 --> Edited by: Ian Lyall Proactive has a commercial relationship with Faron Pharmaceuticals Limited. This article was produced independently under Proactive's Editorial Standards Policy . Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Faron Pharmaceuticals Limited ( AIM:FARN ) View Price & Profile Stifel reiterates Buy on Faron Pharmaceuticals after cash update secures runway to key trial readout Published: 12:30 26 Aug 2026 BST Stifel has reiterated its 'buy' rating on Faron Pharmaceuticals Limited (AIM:FARN) , the Finnish biotech, maintaining a price target of €2.50 after the company's interims, which showed the company well-funded to push on with value-accretive work in the clinic. The stock closed at €0.48 on 25 August, implying upside of 418.1% to the target price. Faron held €32.0 million in cash at the end of June, up from €13.5 million a year earlier, following the completion of a €40.1 million rights issue in April. Stifel said the funding extends Faron's cash runway to November 2027, which is expected to cover the key year-end readout from the company's BEXERA trial. The randomised phase IIb portion of BEXERA is expected to begin in the second half of 2026 and enrol approximately 90 treatment-naive patients with high-risk myelodysplastic syndrome across up to 35 sites in the US, Europe and the UK. The trial will compare two doses of bexmarilimab combined with azacitidine against placebo combined with azacitidine, with complete response as the primary endpoint. Separately, matured BEXMAB data presented at the European Hematology Association congress showed the median duration of complete response had increased to 16.1 months from around 12 months previously, at a median follow-up of 14.9 months. The data showed an 85% overall response rate, a 45% complete response rate and complete bone marrow blast clearance in 60% of patients. A subsequent analysis of the 21-patient frontline cohort showed median overall survival of 8.8 months in a small biallelic TP53-mutated subgroup of 6-7 patients, broadly in line with the 7 to 9 months seen historically in this population. Continue reading